Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future
Open accessThe DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) has no currently approved disease-modifying therapies (DMTs), and treatments to prevent, delay the onset, or slow the progression are urgently needed. A delay of 5 years if available by 2025 would decrease the total number of patients with AD by 50% in 2050. To meet the definition of DMT, an agent must produce an enduring change in the course of AD; clinical trials of DMTs have the goal of demonstrating this effect. AD drug discovery entails target identification followed by high throughput screening and lead optimization of drug-like compounds. Once an optimized agent is available and has been assessed for efficacy and toxicity in animals, it progresses through Phase I testing with healthy volunteers, Phase II learning trials to establish proof-of-mechanism and dose, and Phase III confirmatory trials to demonstrate efficacy and safety in larger populations. Phase III is followed by Food and Drug Administration review and, if appropriate, market access. Trial populations include cognitively normal at-risk participants in prevention trials, mildly impaired participants with biomarker evidence of AD in prodromal AD trials, and subjects with cognitive and functional impairment in AD dementia trials. Biomarkers are critical in trials of DMTs, assisting in participant characterization and diagnosis, target engagement and proof-of-pharmacology, demonstration of disease-modification, and monitoring side effects. Clinical trial designs include randomized, parallel group; delayed start; staggered withdrawal; and adaptive. Lessons learned from completed trials inform future trials and increase the likelihood of success.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Decades of intensive research on a relatively narrow set of pathogenic processes occurring in the brain and body have produced few effective new drugs or other significant advances in the prevention and treatment of Alzheimer’s disease and related dementias (ADRD).1–3”
From Why the cognitive ‘fountain of youth’ may be upstream: pathways to dementia risk and resilience through social connectedness (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these treatments, whose effectiveness is only partial and temporary at best, affect only the consequences of AD rather than the cause [1,17,157,158].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [158]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Timely intervention may be important and emphasizes the need for better diagnosis of the early stages of AD using additional biomarkers [158].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Self-citation2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Self-citationAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 12×
“Placebo decline determines drug-placebo difference Successful DMTs will slow the course of decline in AD.”
BackgroundInfluentialSelf-citationREDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344 · cited 1×
“Drugs that have genetic connections to the neurobiology of the disease and that have biomarkers to inform drug development decisions are more likely to advance from one phase to the next than drugs that lack this information [57].”
BackgroundA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
A three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · The American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 900
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 2×
“Finally, MRI is used to monitor amyloid-related imaging abnormalities (ARIA) occurring as a side effect in patients treated with some anti-amyloid mAbs [44].”
BackgroundMethodTau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734 · cited 1×
“Tau PET correlates better with cognitive decline and MRI measures of brain atrophy and may provide more insight into DM than amyloid measures [77, 78].”
BackgroundPhase II and phase III failures: 2013–2015
Harrison, R. K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.184 · Cited by 636
Learning versus confirming in clinical drug development*
Sheiner, L. B. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90160-0 · Cited by 633 · cited 1×
“Phase II and Phase III are often conceived as “learn” and “confirm” trials [55].”
Functional Alterations in Memory Networks in Early Alzheimer’s Disease
Sperling, R. A., Dickerson, B. C., Pihlajamaki, M., Vannini, P., LaViolette, P. S., Vitolo, O. V., Hedden, T., Becker, J. A., Rentz, D. M., Selkoe, D. J., et al. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8109-7 · Cited by 604
Epidemiology of Dementias and Alzheimer’s Disease
Sosa-Ortiz, A. L., Acosta-Castillo, I., & Prince, M. J. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.11.003 · Cited by 553
How to Use a Subgroup Analysis: Users’ Guide to the Medical Literature
Sun, X., Ioannidis, J. P. A., Agoritsas, T., Alba, A. C., & Guyatt, G. (2014) · JAMA · doi:10.1001/jama.2013.285063 · Cited by 550
Alzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549 · cited 1×
“small molecule agents administered orally [7, 8].”
Self-citationOn The Rate and Extent of Drug Delivery to the Brain
Hammarlund-Udenaes, M., Fridén, M., Syvänen, S., & Gupta, A. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9502-2 · Cited by 513
Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · cited 1×
“Allele status may affect efficacy and side effects and often influences dosing in mAb trials [42, 44, 45].”
BackgroundZetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487 · cited 1×
“DM is supported by an impact on “downstream” measures of cell death such as MRI atrophy, CSF tau, or possibly other biomarkers of neuronal degeneration such as neurofilament light chain protein [54].”
BackgroundAlzheimer disease therapy—moving from amyloid-β to tau
Giacobini, E., & Gold, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.223 · Cited by 471
Donohue, M. C., Sperling, R. A., Petersen, R., Sun, C.-K., Weiner, M. W., Aisen, P. S., & Initiative, F. T. A. D. N. (2017) · JAMA · doi:10.1001/jama.2017.6669 · Cited by 452
Animal Models of Alzheimer Disease
LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419
Key Concepts of Clinical Trials: A Narrative Review
Umscheid, C. A., Margolis, D. J., & Grossman, C. E. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2475 · Cited by 410
Credibility of claims of subgroup effects in randomised controlled trials: systematic review
Sun, X., Briel, M., Busse, J. W., You, J. J., Akl, E. A., Mejza, F., Bala, M. M., Bassler, D., Mertz, D., Diaz-Granados, N., et al. (2012) · BMJ · doi:10.1136/bmj.e1553 · Cited by 395
MRI correlates of neurofibrillary tangle pathology at autopsy: A voxel-based morphometry study
Whitwell, J. L., Josephs, K. A., Murray, M. E., Kantarci, K., Przybelski, S. A., Weigand, S. D., Vemuri, P., Senjem, M. L., Parisi, J. E., Knopman, D. S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324924.91351.7d · Cited by 376
Babiloni, C., Lizio, R., Marzano, N., Capotosto, P., Soricelli, A., Triggiani, A. I., Cordone, S., Gesualdo, L., & Del Percio, C. (2016) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2015.02.008 · Cited by 359
Biomarkers and surrogate markers: An FDA perspective
Katz, R. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.189 · Cited by 347
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A. S., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F., & Tariot, P. N. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0059 · Cited by 339
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330
Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Cummings, J. (2018) · Clinical and Translational Science · doi:10.1111/cts.12491 · Cited by 298
Self-citationWang, L., Benzinger, T. L., Su, Y., Christensen, J., Friedrichsen, K., Aldea, P., McConathy, J., Cairns, N. J., Fagan, A. M., Morris, J. C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2078 · Cited by 293
Karran, E., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 275
Blood–brain-barriers in aging and in Alzheimer’s disease
Marques, F., Sousa, J. C., Sousa, N., & Palha, J. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-38 · Cited by 274
A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials
Harrison, J., Minassian, S. L., Jenkins, L., Black, R. S., Koller, M., & Grundman, M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.9.1323 · Cited by 225
Rodent models for Alzheimer’s disease drug discovery
Puzzo, D., Gulisano, W., Palmeri, A., & Arancio, O. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1041913 · Cited by 222
Ritchie, C. W., Molinuevo, J. L., Truyen, L., Satlin, A., Van der Geyten, S., & Lovestone, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00454-x · Cited by 202
Mormino, E. C., Papp, K. V., Rentz, D. M., Donohue, M. C., Amariglio, R., Quiroz, Y. T., Chhatwal, J., Marshall, G. A., Donovan, N., Jackson, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.018 · Cited by 202
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Galasko, D., Bell, J., Mancuso, J. Y., Kupiec, J. W., Sabbagh, M. N., van Dyck, C., Thomas, R. G., Aisen, P. S., & Study, F. T. A. D. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000364 · Cited by 187
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184 · cited 1×
“Observations made from CSF in the healthy state must later be confirmed in the disease state as differences in cerebral blood flow, activity of efflux transport proteins, and BBB permeability with disease may fundamentally alter drug delivery [35].”
BackgroundFauman, E. B., Rai, B. K., & Huang, E. S. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.020 · Cited by 181
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
Wang, J., Logovinsky, V., Hendrix, S. B., Stanworth, S. H., Perdomo, C., Xu, L., Dhadda, S., Do, I., Rabe, M., Luthman, J., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312383 · Cited by 160
Self-citationPreclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial
Mills, S. M., Mallmann, J., Santacruz, A. M., Fuqua, A., Carril, M., Aisen, P. S., Althage, M. C., Belyew, S., Benzinger, T. L., Brooks, W. S., et al. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.017 · Cited by 139
DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE
Cummings, J., & Fox, N. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.12 · Cited by 139
Self-citationAccelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies
Shineman, D. W., Basi, G. S., Bizon, J. L., Colton, C. A., Greenberg, B. D., Hollister, B. A., Lincecum, J., Leblanc, G. G., Lee, L. (. H., Luo, F., et al. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt90 · Cited by 137
Langbaum, J. B., Hendrix, S. B., Ayutyanont, N., Chen, K., Fleisher, A. S., Shah, R. C., Barnes, L. L., Bennett, D. A., Tariot, P. N., & Reiman, E. M. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.002 · Cited by 128
Adaptive Clinical Trial Design
Chow, S.-C. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112310 · Cited by 124
Utility of CSF in translational neuroscience
de Lange, E. C. M. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9301-9 · Cited by 119
Sevigny, J., Suhy, J., Chiao, P., Chen, T., Klein, G., Purcell, D., Oh, J., Verma, A., Sampat, M., & Barakos, J. (2016) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000144 · Cited by 114
Alzheimer's drug‐development pipeline: 2016
Cummings, J., Morstorf, T., & Lee, G. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.07.001 · Cited by 108 · cited 2×
“Approximately two-thirds of the current AD drug development pipeline involves DMTs—either immunotherapies or small molecule agents administered orally [7, 8].”
BackgroundSelf-citationCSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease
Tarawneh, R., Lee, J.-M., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2012) · Neurology · doi:10.1212/wnl.0b013e318248e568 · Cited by 107
Evaluation of blockbuster drugs under the Rule-of-five
Giménez, B. G., dos Santos, M. S., Ferrarini, M., Fernandes, J. P. S., & Fernandes, J. P. S. (2010) · Die Pharmazie · doi:10.31083/ph.2010.9733 · Cited by 106
Slowing the progression of Alzheimer disease: methodologic issues.
Leber, P. D. (1997) · PubMed · Cited by 104
Cummings, J., Froelich, L., Black, S. E., Bakchine, S., Bellelli, G., Molinuevo, J. L., Kressig, R. W., Downs, P., Caputo, A., & Strohmaier, C. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000340056 · Cited by 96
Self-citationSafety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease
Farlow, M., Veloso, F., Moline, M., Yardley, J., Brand-Schieber, E., Bibbiani, F., Zou, H., Hsu, T., & Satlin, A. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-57 · Cited by 95
Liu, Q., Waltz, S., Woodruff, G., Ouyang, J., Israel, M. A., Herrera, C., Sarsoza, F., Tanzi, R. E., Koo, E. H., Ringman, J. M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2482 · Cited by 91
A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents
Appleby, B. S., Nacopoulos, D., Milano, N., Zhong, K., & Cummings, J. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000345791 · Cited by 90
Self-citationHigh-content analysis in neuroscience
Dragunow, M. (2008) · Nature reviews. Neuroscience · doi:10.1038/nrn2492 · Cited by 88
Economic analysis of opportunities to accelerate Alzheimer's disease research and development
Scott, T. J., O'Connor, A. C., Link, A. N., & Beaulieu, T. J. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12417 · Cited by 87
Observations and Suggestions on Antidementia Drug Development
Leber, P. (1996) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199601031-00009 · Cited by 87
Experimental models for predicting drug absorption and metabolism
Alqahtani, S., Mohamed, L. A., & Kaddoumi, A. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.802772 · Cited by 86
Wessels, A. M., Siemers, E. R., Yu, P., Andersen, S. W., Holdridge, K. C., Sims, J. R., Sundell, K., Stern, Y., Rentz, D. M., Dubois, B., et al. (2015) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2015.82 · Cited by 86
Self-citationDiscovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Appleby, B., & Cummings, J. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660162 · Cited by 79
Self-citationExploratory drug safety: A discovery strategy to reduce attrition in development
Bass, A. S., Cartwright, M. E., Mahon, C., Morrison, R. A., Snyder, R. D., McNamara, P., Bradley, P. K., Zhou, Y., & Hunter, J. (2009) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2009.04.194 · Cited by 78
Selection, design, and engineering of therapeutic antibodies
Presta, L. G. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.08.003 · Cited by 72
Neuropsychological Assessment of the Severely Impaired Elderly Patient
Saxton, J. A., & Swihart, A. A. (1989) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30669-4 · Cited by 70
Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases
Katsuno, M., Tanaka, F., & Sobue, G. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301307 · Cited by 60
Grill, J. D., Di, L., Lu, P. H., Lee, C., Ringman, J., Apostolova, L. G., Chow, N., Kohannim, O., Cummings, J. L., Thompson, P. M., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.006 · Cited by 58
Self-citationAntibody-based therapy in Alzheimer's disease
Pul, R., Dodel, R., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 58
Initiative, A. D. N., Liu, Y., Tan, L., Wang, H.-F., Liu, Y., Hao, X., Tan, C., Jiang, T., Liu, B., Zhang, D., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9388-7 · Cited by 57
RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK
Cummings, J., Aisen, P., Barton, R., Bork, J., Doody, R., Dwyer, J., Egan, J. C., Feldman, H., Lappin, D., Truyen, L., et al. (2016) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2016.93 · Cited by 55
Self-citationThe target product profile as a tool for regulatory communication: advantageous but underused
Tyndall, A., Du, W., & Breder, C. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.264 · Cited by 49
Liu-Seifert, H., Andersen, S. W., Lipkovich, I., Holdridge, K. C., & Siemers, E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119632 · Cited by 44
The Impact of Preclinical Irreproducibility on Drug Development
Freedman, L., & Gibson, M. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.9 · Cited by 43
Amyloid-β1-15/16 as a Marker for γ-Secretase Inhibition in Alzheimer's Disease
Portelius, E., Zetterberg, H., Dean, R. A., Marcil, A., Bourgeois, P., Nutu, M., Andreasson, U., Siemers, E., Mawuenyega, K. G., Sigurdson, W. C., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120508 · Cited by 42
Bodick, N. C., Forette, F., Hadler, D., Harvey, R. J., Leber, P. D., McKeith, I. G., Riekkinen, P. J., Rossor, M. N., Scheltens, P., Shimohama, S., et al. (1997) · PubMed · doi:10.25405/ncl.34092027 · Cited by 42
Measuring behavior, mood, and psychiatric symptoms in Alzheimer disease.
Teri, L., Logsdon, R., & Yesavage, J. A. (1997) · PubMed · Cited by 39
CNS Amyloid- , Soluble APP- and - Kinetics during BACE Inhibition
Dobrowolska, J. A., Michener, M. S., Wu, G., Patterson, B. W., Chott, R., Ovod, V., Pyatkivskyy, Y., Wildsmith, K. R., Kasten, T., Mathers, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0540-14.2014 · Cited by 37
Globalization of Alzheimer's disease clinical trials
Cummings, J., Reynders, R., & Zhong, K. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt86 · Cited by 37
Self-citationAlzheimer’s disease progression by geographical region in a clinical trial setting
Henley, D. B., Dowsett, S. A., Chen, Y.-F., Liu-Seifert, H., Grill, J. D., Doody, R. S., Aisen, P., Raman, R., Miller, D. S., Hake, A. M., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0127-0 · Cited by 35
Self-citationSchreiber, S., Schreiber, F., Lockhart, S. N., Horng, A., Bejanin, A., Landau, S. M., Jagust, W. J., & Initiative, A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5349 · Cited by 35
Grill, J. D., Raman, R., Ernstrom, K. B., Aisen, P. S. S., Dowsett, S. A., Chen, Y.-F., Liu‐Seifert, H., Hake, A. M., Miller, D. S., Doody, R. S., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0122-5 · Cited by 32
Self-citationAlzheimer's disease biomarkers in animal models: closing the translational gap.
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Europe PMC (PubMed Central) · Cited by 31
Self-citationOptimizing phase II of drug development for disease‐modifying compounds
Cummings, J. L. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.10.002 · Cited by 31
Self-citationWan, H. I., Jacobsen, J. S., Rutkowski, J. L., & Feuerstein, G. Z. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2009.00121.x · Cited by 30
The dose-response relationship in Phase I clinical trials and beyond use, meaning, and assessment
Emilien, G. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00077-2 · Cited by 30
A Map of Alzheimer’s Disease–Signaling Pathways: A Hope for Drug Target Discovery
Ogishima, S., Mizuno, S., Kikuchi, M., Miyashita, A., Kuwano, R., Tanaka, H., & Nakaya, J. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.37 · Cited by 29
Advances in quantitative structure–activity relationship models of anti-Alzheimer’s agents
Ambure, P. S., & Roy, K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.909404 · Cited by 25
Hölttä, M., Dean, R. A., Siemers, E., Mawuenyega, K. G., Sigurdson, W. C., May, P. C., Holtzman, D. M., Portelius, E., Zetterberg, H., Bateman, R. J., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0178-x · Cited by 21
Thomas, R. G., Albert, M., Petersen, R. C., & Aisen, P. S. S. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.002 · Cited by 19
Examination of risk evaluation and mitigation strategies and drug safety in the US
Rodríguez-Monguió, R., Spielberger, K., & Seoane-Vazquez, E. C. (2013) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2013.03.005 · Cited by 17
Zippo, A. G., & Castiglioni, I. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666151116142451 · Cited by 17
Innovation in Therapeutics Development at the NCATS
Colvis, C. M., & Austin, C. P. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.247 · Cited by 13
(2023) · Palgrave Macmillan UK eBooks · doi:10.1057/978-1-349-96073-6_16331 · Cited by 10
Drug Development in Alzheimer’s Disease—The Role of Default Mode Network Assessment in Phase II
Cummings, J. L., Zhong, K., Global Alzheimer’s Platform, W., & Cordes, D. (2017) · touchREVIEWS in Neurology · doi:10.17925/usn.2017.13.02.67 · Cited by 9
Self-citationSun, H., & Vach, W. (2015) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2015.1052484 · Cited by 4
Dose Selection for First-in-Human (FIH) Trials—Regulatory Perspective
Freed, L. M. (2006) · Drugs and the pharmaceutical sciences · doi:10.1201/9781420018585.ch4 · Cited by 3
Research works printed but not linked: 1
- Cummings, 2017, Defining disease modification for Alzheimer’s disease clinical trials, J Prev Alzheimers Dis, 4, 109
Cited by
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Monteiro, A. R., Barbosa, D. J., Remião, F., & Silva, R. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115522 · Cited by 329
Orr, M., Gonzales, M., Garbarino, V., Kautz, T., Palavicini, J., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J., Zare, H., Xu, P., et al. (2023) · doi:10.21203/rs.3.rs-2809973/v1 · Cited by 319
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial
Gonzales, M. M., Garbarino, V. R., Kautz, T. F., Palavicini, J. P., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J. J., Zare, H., Xu, P., Zhang, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02543-w · Cited by 334
Metadata
- Authors
- Cummings, J., Ritter, A., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Global Alzheimer's Platform Foundation (US)
- Corresponding author
- Cummings, Jeffrey
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S3-S22
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004914
- OpenAlex
- W2789238556
- Cited by
- 176
- References
- 114
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 14 · 2023: 19 · 2022: 25 · 2021: 38 · 2020: 18 · 2019: 22 · 2018: 5
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (P20GM109025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Animals, Clinical Trials as Topic, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.